MetaCap

Filana Therapeutics (FLNA) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed Filana Therapeutics (FLNA) over the past year, losing 38.6% versus a loss of 77.7%. Over five years, NXTC leads with a -91.1% price change compared with -98.9% for FLNA. Filana Therapeutics is the larger company by market cap ($32.3 million vs $29.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FLNA-77.66%NXTC-38.63%
+42%-25%-91%
Nov 21, 20251 yearNov 20, 2026
FLNA-98.79%NXTC-90.73%
+12%-46%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FLNA versus NXTC key metrics
MetricFLNANXTC
Share price$0.6413$6.45
Market cap$32.26M$29.53M
1-day change+14.52%-4.87%
YTD return-67.61%-54.55%
1-year return-77.66%-38.63%
5-year return-98.85%-91.07%
EPS (TTM)$-0.87$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-90.97M$-55.84M
52-week high$3.45$15.74
52-week low$0.39$1.55
Distance from 52-week high-81.41%-59.02%
Analyst consensusnonenone
Avg. price target upside+913.57%+210.08%
Average volume2.09M79.46K
Shares outstanding50.30M4.58M
Employees1740
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed FLNA by 39.0 percentage points over the past year.

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

FLNA vs NXTC FAQ

Which is bigger, Filana Therapeutics or NextCure?

Filana Therapeutics (FLNA) is larger, with a market capitalization of $32.26M compared with $29.53M for NextCure (NXTC).

Which stock has performed better over the past year, FLNA or NXTC?

NXTC returned -38.63% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Filana Therapeutics and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons